Treatment of migraines
Provided herein are prostaglandin F 2α analog compositions and methods for treating migraines.
1. A method of treating migraine in a subject in need thereof, the method comprising oral or mucosal membrane administration of a composition comprising latanoprost, isopropyl unoprostone, bimatoprost, travoprost, or tafluprost, or a pharmaceutically acceptable salt thereof, to the subject, in an amount effective to treat migraine; provided that the mucosal membrane is not an eye.
2. The method of claim 1 , wherein the administration to the subject reduces the frequency of migraines in the subject.
3. The method of claim 1 , wherein the administration to the subject is therapeutic.
4. The method of claim 1 , wherein the administration to the subject is oral administration.
5. The method of claim 1 , wherein the administration to the subject is administration to a mucous membrane.
6. The method of claim 5 , wherein the mucous membrane is of the rectum, nose, throat, lungs, or buccal cavity.
7. The method of claim 5 , wherein the administration is sublingual, suppository, or inhaled delivery.
8. The method of claim 1 , wherein the composition comprises bimatoprost, travoprost, or latanoprost, or a pharmaceutically acceptable salt thereof.
9. The method of claim 1 , wherein the composition comprises bimatoprost, or a pharmaceutically acceptable salt thereof.
10. A method of treating migraine in a subject in need thereof, the method comprising sustained release administration of a composition comprising latanoprost, isopropyl unoprostone, bimatoprost, travoprost, or tafluprost, or a pharmaceutically acceptable salt thereof, to the subject, in an amount effective to treat migraine.
11. The method of claim 10 , wherein the administration to the subject reduces the frequency of migraines in the subject.
12. The method of claim 10 , wherein the administration to the subject is therapeutic.
13. The method of claim 10 , wherein the sustained release administration to the subject is oral administration.
14. The method of claim 10 , wherein the sustained release administration to the subject is topical administration.
15. The method of claim 14 , wherein the topical administration comprises delivery of the composition by a transdermal delivery system.
16. The method of claim 15 , wherein the transdermal delivery system is a drug-containing device which releases one or more drugs at a predetermined rate.
17. The method of claim 10 , wherein the composition comprises bimatoprost, travoprost, or latanoprost, or a pharmaceutically acceptable salt thereof.
18. The method of claim 10 , wherein the composition comprises bimatoprost, or a pharmaceutically acceptable salt thereof.
19. A method of treating migraine in a subject in need thereof, the method comprising administering, to the eye of the subject, a composition comprising isopropyl unoprostone, bimatoprost, travoprost, or tafluprost, or a pharmaceutically acceptable salt thereof, in an amount effective to treat migraine.
20. The method of claim 19 , wherein the administration to the subject is reduces the frequency of migraines in the subject.
21. The method of claim 19 , wherein the administration to the subject is therapeutic.
22. The method of claim 19 , wherein the composition comprises bimatoprost or travoprost, or a pharmaceutically acceptable salt thereof.
23. The method of claim 19 , wherein the composition comprises bimatoprost, or a pharmaceutically acceptable salt thereof.